Volume of buyback does seem to have stepped up a gear.
==============================
Date of purchase: 19/11/2024
Number of ordinary shares purchased: 600,000
Volume weighted average price paid per ordinary share (GBp): 41.9852
==============================
Date of purchases: 18/11/2024
Number of ordinary shares purchased: 340,000
Volume weighted average price (pence): 43.6640
==============================
Total volume on 19/11/2024 approx 2.6m
Total volume on 18/11/2024 approx 4.3m
[edit, typo, total volume figs switched around, correct now] |
We're probably mostly long on this thread, but I struggle to see a viable strategy for shorting IP Group.
After all, cash + Featurespace + listed companies is fairly close to the current market cap. IPO could easily launch a tender / large buyback and blow away any shorts.
I also don't see how a long ONT (+ other IP components) and short IPO semi-hedge strategy makes a lot of sense.
It could just be a very short term play on bad sentiment around drugmakers with the RFK appointment??? |
Qube showing a 0.5% short position, since around 15/11/2024
Always interested on others' take on these things.
Systematica Investments Limited showing 0.5% short position in ONT
Hoping management are using the buyback to our benefit! |
nigel, afaik, management order and write the rules of the buyback. I understand they don't do the actual buying, as this would possibly create a conflict of interest.
Another poster 'palisz' suggested [although I might have misunderstood] that management made the instruction. See post 3310
"...The formula goes like this.
Excluding opening and closing cross the broker targets the VWAP ( volume weighted average price) IPO just has to say what percentage it wants. At the end of the previous tranche of buy back this was set as high as 20%.
This time it seems to be around 10% but I haven't been checking so much.
The normal range is 5 - 20% depending on liquidity and the CEO's whim!
The CEO can change the % at any time, without notice. With IPO this has happened a number of times. Often it depends if there is further buying power to come." |
They are being cancelled log. See RNS each day. |
Would not surprise me at all if a lot of the buy back they gave to staff as share based comp. |
They're not. Numis are executing on their behalf. Mgmt have no say in what price trades are executed at. |
Antrox
Date of purchases: 18/11/2024
Number of ordinary shares purchased: 340,000
Volume weighted average price (pence): 43.6640
==============================================
Management do seem to be aware of share price volatility, and are seemingly attempting to average in over the period of the buyback. |
Dummy questions.
I have not seen any RNS about "Transaction in Own Shares" today.
1) Does it mean that the buyback has not been done today and this has caused the share price plummeted?
2) would not be more convenient for a company to buy back shares at low instead of high SP?
I think it can go as low as 35p but I am curious to see if it bounces back tomorrow |
It's not 10% of market cap tho is it? |
Weird that this is down so hard today. ONT has been weak the last few days but given that it's maybe 10% of NAV, that doesn't really begin to explain the size of today's move. I reckon that it's either that Istesso's clinical trial results are bad and have leaked or, more likely, it's a response to RFK's nomination to HHS which many are interpreting as likely to cause chaos to the FDA's drug approval process. If the latter, then seems an extreme overreaction given IP is already on a monster discount and far from solely focused on drug discovery. But, as ever, who knows! |
craig the current buyback started on the Monday 7/10/24.
Up to last Friday 15/11/24 the co. had bought back approx 6,357,498 shares.
At £0.50 each this would mean approx £3,178,749 of the £10,000,000 has been spent.
They planned to spend £10m before the end of 2024. |
ONT being shorted and trashed probably has something to do with it, unless someone has wind of the Istesso results. |
This stock is so bad at holding any f’ing gains! Catching a falling knife everytime
I don’t get it but seems to have no love
D |
Anybody tracking how much of the £10m of buybacks has been spent so far?
They'd better pick up the pace or we'll be back below 40p before too long... |
 IP Group plc - Australian portfolio company AMSL Aero completes first free flight of its 'Vertiia' aircraft
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to note that Australian portfolio company AMSL Aero has announced that it has completed the first free flight of Vertiia, Australia's first passenger-capable, emission-free, long range electric vertical take-off and landing aircraft (eVTOL) aircraft.
The landmark flight is the first by an Australian-designed and built eVTOL, the new generation of aircraft that take off and land like a helicopter but fly fast and smoothly like a fixed-wing aeroplane. Since the first untethered flight, which took place earlier this month, the aircraft has since taken off, flown and landed successfully more than 50 times.
Vertiia is the most complex civil aircraft ever developed in Australia. It has been designed to fly up to 1,000km on hydrogen at a cruising speed of 300km/hour with zero carbon emissions, carrying up to four passengers and a pilot.
The historic test flight was performed on battery power by remote control in the Central West region of New South Wales in accordance with Civil Aviation Safety Authority (CASA) regulations. AMSL Aero will begin hydrogen-fuelled flight testing of Vertiia in 2025 having already broken records in 2023 by completing the first tethered battery-powered hover.
This year, AMSL Aero received deposits for 26 Vertiia aircraft orders from civil customers including 20 from Aviation Logistics, which operates the Air Link, AirMed and Chartair brands covering passenger services, aircraft charter, air freight and aeromedical flights across Australia.
IP Group Australia has an undiluted holding of 34.0% in AMSL Aero while IP Group's managed private funds* hold an additional 14.7%.
*Includes funds managed/advised on behalf of Hostplus & TelstraSuper |
Always thought this was a very long shot in the portfolio but good luck to them. |
Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
13 Nov 2024
Cambridge, UK – 13 November 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial is due to recruit up to 30 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial data readouts are expected by the end of 2025.
Ulcerative colitis, an inflammatory bowel disease, is a debilitating disease that affects over 1.4 million people globally. MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC patients, without immunosuppression or unwanted side effects.
The COMPOSER-1 study will investigate the safety, tolerability, and initial signals of efficacy of MB310 in a randomised, placebo-controlled, double-blind, clinical trial. The degree to which the bacteria within MB310 successfully engraft into patients’ intestinal microbial community will be measured. The study will recruit patients with active, mild-to-moderate UC, who will take two capsules of study medication (active or matched placebo) once a day for 12 weeks in addition to their standard of care medication, with a 12-week follow-up period. (Study identifiers: NCT06582264; 2023-507376-50) .
The bacterial strains in MB310 were identified by analysing clinical and microbiome data from a faecal microbiota transplant (FMT) study in UC patients carried out with collaborators at the University of Adelaide. The results demonstrated the ability of a microbiome therapy to induce remission in UC without significant side-effects. Microbiotica‘s analysis identified the engrafting bacteria associated with clinical response, leading to the development of MB310 as an LBP. Preclinical studies have demonstrated that MB310 acts via at least three independent mechanisms that are central to the pathology of UC: promoting the healing of the damaged gut epithelial barrier, regulating the balance of cytokines that are inflammatory (TNF) and immune-modulatory (IL-10); and inducing a regulatory T-cell response.
Professor Walter Reinisch, Professor for Gastroenterology and Hepatology at the Vienna Medical University, Austria, an advisor to Microbiotica and a principal investigator in the study, said, “Microbiota dysregulation is known to be a key driver to the pathogenesis in ulcerative colitis. The COMPOSER-1 study offers us a unique opportunity to treat UC by rebalancing the microbiota with this new treatment modality and potentially inducing long-term disease remission in our patients.”
Ron Carter, Microbiotica’s Chief Medical Officer, said, “there is a considerable body of evidence to support that FMT is beneficial for mild-to-moderate UC patients. This provides the underpinning of a microbiome-based treatment for this debilitating disease. Microbiotica’s precision microbiome platform has enabled us to identify the specific bacteria that could make a difference for patients and deliver them as a pharmaceutical in the form of MB310.”
– ENDS –
About Microbiotica
Microbiotica is a private, clinical-stage, biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programmes in immuno-oncology and inflammatory bowel disease. The company has a clinic-led, purpose-built, proprietary, microbiome profiling platform to support drug discovery based on clinical data, which enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.
The Company is creating a novel pipeline of programmes in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis). It has a major partnership with Cancer Research UK and Cambridge University Hospitals in immuno-oncology. The company has a clinical trial supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA in evaluating MB097 in melanoma patients with primary resistance to anti-PD-1 immunotherapy. MB310 was developed in collaboration with the University of Adelaide. Both programmes have data read-outs in 2025.
Spun out of the Wellcome Sanger Institute in 2016, the Company is based in purpose-built facilities at the Chesterford Research Park near Cambridge, UK. Microbiotica has raised more than £62 million equity investment, including a £50 million Series B in 2022, with venture investors including British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent. The company has also received financial support from the US-based Crohn’s and Colitis Foundation. |
Having found a base, chart finally starting to look more positive. |
Thanks, This looks like a new trial. They haven't reported the results of the other 3 yet. IP Group could easily provide an update, rather than choosing to keep the Shareholders in the dark. |
Checking up on Istesso trial, found this that seems to suggest still recruiting and a 31 December 2024 end date. |
New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore
05 Nov 2024
New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore designed to:
Advance biomedical research and translate discoveries for improved patient care
Improve health outcomes by targeting novel genomic and epigenomic discoveries in cancer, human genetic disease and infectious disease
Initial programme: to create an ‘early warning system’ for future pandemics across as many as 30 NHS sites, to support improved biosecurity nationwide
Oxford Nanopore’s high-performance genomics technology to provide richer genomic data, faster, more accessibly and more affordably.
Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore, to support the government’s vision to build an NHS “fit for the future" by enabling genomics-based translational research and accelerating the development and adoption of Oxford Nanopore’s ground-breaking genomics technology in the NHS.
By utilising Oxford Nanopore’s richer genomic insights, rapid, scalable and affordable sequencing technology, the initiative aims to deliver transformative improvements in patient care and foster economic growth in the UK’s thriving life sciences sector.
Oxford Nanopore CEO Gordon Sanghera, commented:
“The UK has a remarkable genomics ecosystem, and we are delighted to be innovating more collaboratively through this partnership. Genomics England and UK Biobank have led the way in scaling genomics discovery and translating these advances into patient impact. NHS England, through its Networks of Excellence and advancements developed by the Genomic Laboratory Hubs (GLHs), has been instrumental in adopting these innovations into national healthcare strategies. By working alongside our partners on shared goals of improved patient outcomes - whether in cancer, human genetic disease or infectious disease - we believe we can deploy our unique DNA/RNA sequencing technology in ways that are most impactful for the people of the UK.”
Health and Social Care Secretary Wes Streeting, commented:
“If we fail to prepare, we should prepare to fail. Our NHS was already on its knees when the pandemic struck, and it was hit harder than any other comparable healthcare system.
“We cannot let history repeat itself. That’s why this historic partnership with Oxford Nanopore will ensure our world-leading scientists have the latest information on emerging threats at their fingertips.
“As we embrace the technological revolution, our 10 Year Health Plan will shift the NHS away from analogue to digital, saving countless more lives.”
Science and Technology Secretary Peter Kyle, commented:
“During the Covid pandemic we saw the power of the UK life sciences sector very clearly – from the Oxford-Astra Zeneca vaccine that saved so many lives, through to operating one of the world’s most effective Covid surveillance systems, which spotted several emerging variants of the disease.
“This partnership will build on that expertise to monitor emerging diseases as they arise, putting our scientists and decision-makers one-step ahead and providing the information they need to make informed decisions.
“Together with the ability to better diagnose cancers and rare diseases, we are leveraging UK life sciences to protect the public and ultimately save lives.”
Professor Susan Hopkins, Chief Medical Advisor at UK Health Security Agency, commented:
“Early detection is absolutely crucial in enabling us to respond effectively to any emerging pathogen. The UK already has a wealth of expertise in genomic surveillance, and this programme will build on that expertise and enable us to bring our resources and capability to tackle developing threats at greater speed. Enhancing the capacity for the NHS to determine new and emerging pathogens causing severe acute respiratory infections will improve the detection and emergence of infections.
“As part of the 100 days mission, this will enable the development of effective diagnostics for novel pathogens and enhance our pandemic preparedness.”
Professor Ian Abbs, Chief Executive of Guy’s and St Thomas’ NHS Foundation Trust, commented:
“We’ve been working on the respiratory metagenomics programme for over four years and have clearly seen the benefit to our patients. It’s a momentous day now that we can ensure other hospitals, and more patients, can also benefit from faster and more accurate treatment for severe respiratory conditions thanks to new genomic technology.”
Advancing the understanding of genomics, for future disease prevention and personalised medicine
Oxford Nanopore’s partnership with Genomics England and UK Biobank is aimed at translating research-based discoveries from the lab into clinical settings, benefiting UK healthcare. Priority areas include cancer, where genomic insights (the analysis of DNA) can help identify personalised treatment options and enhance early detection, and rare disease characterisation, where information-rich genomic and epigenetic analysis – changes to DNA that contribute to disease – can improve diagnosis and inform targeted therapies. This partnership presents a further opportunity to collaborate on broader emerging applications, which in the future could include newborn screening, where genomics can enable early identification of genetic disorders for prompt intervention, and pharmacogenomics, where genetic insights guide safer and more effective medication choices tailored to an individual's genetic profile.
Creating a world-first pathogen surveillance system in the NHS
As a key part of the partnership, the UK will establish the first real-time, pathogen-agnostic biosurveillance system across as many as 30 hospitals in NHS England—a crucial early warning framework to detect and respond to emerging pandemics and biological threats. Building on successful NHS England Network of Excellence pilots led by Guy’s and St Thomas’ NHS Foundation Trust (GSTT), this system will expand the NHS Respiratory Metagenomics programme to enable rapid pathogen identification across the UK. This data will be provided by the NHS to the UK Health and Security Agency, allowing potentially quicker decisions on emerging diseases to be taken and bolstering national biosecurity as set forth in the UK Biological Security Strategy. This project is expected to start in 2025 and will continue over multiple years.
In addition to providing biosecurity capabilities, the expanded respiratory metagenomics programme will deploy Oxford Nanopore’s sequencing technology to support infectious disease management in the critical care setting. This rollout is designed to provide a groundbreaking, six-hour timeline for fully characterising respiratory diseases including drug (antimicrobial) resistance, an essential leap forward in patient care. By rapidly transitioning NHS diagnostics from analogue to digital, the programme’s goal is to enable quicker, targeted care for patients and reduce hospital strain, advancing the ambitions set out in the Government’s 10-Year Health Plan.
Translating genomics into enhanced NHS patient care
The integration of Oxford Nanopore’s innovative sequencing technology will enable the NHS to explore further this technology to characterise diseases including cancer and rare genetic conditions with greater speed and precision. With potential for collaborative development of rapid and improved diagnostic tools, Oxford Nanopore’s technology has the potential to enable patients across the NHS to benefit from earlier, more accurate disease detection and treatment pathways.
Driving economic growth and workforce development in life sciences
This work will not only enhance patient outcomes but also position the UK as a global leader in genomic research and innovation, further strengthening the nation’s biosecurity and healthcare resilience. By accelerating pathways for life sciences innovation into the NHS through globally recognised research programmes, this collaboration enhances the UK’s position as a global biotechnology hub, supporting economic growth and creating high-value jobs in the life sciences ecosystem. As part of this initiative, NHS staff and researchers will gain access to relevant training and support to advance a skilled workforce ready to harness the potential of genomics and personalised medicine. |
TRX up for sale. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
